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Abstract:  Breast cancer is the most prevalent disease amongst women worldwide and 
metastasis is the main cause of death due to breast cancer. Metastatic breast cancer cells 
and embryonic stem (ES) cells display similar characteristics. However, unlike metastatic 
breast cancer cells, ES cells are nonmalignant. Furthermore, embryonic microenvironments 
have the potential to convert metastatic breast cancer cells into a less invasive phenotype. 
The creation of in vitro embryonic microenvironments will enable better understanding of 
ES cell-breast cancer cell interactions, help elucidate tumorigenesis, and lead to the 
restriction of breast cancer metastasis. In this article, we will present the characteristics of 
breast cancer cells and ES cells as well as their microenvironments, importance of 
embryonic microenvironments  in inhibiting tumorigenesis, convergence of tumorigenic 
and embryonic signaling pathways, and state of the art in  bioengineering  embryonic 
microenvironments for breast cancer research. Additionally, the potential application of 
bioengineered embryonic microenvironments for the prevention and treatment of invasive 
breast cancer will be discussed. 
Keywords:  stem cell; microenvironment; hydrogel; three-dimensional culture; breast 
cancer; metastasis; co-culture 
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1. Introduction 
According to the International Agency for Research on Cancer, breast cancer is the most frequently 
diagnosed malignant disease and leading cause of cancer deaths among women worldwide. In 2011, it 
is estimated that 230,480 women in the United States will be diagnosed with invasive breast cancer 
and 57,650 with noninvasive breast cancer, from which 39,520 women will die [1]. Despite the fact 
that the death rate of breast cancer is expected to decrease due to better awareness, early detection and 
improved treatment, it is anticipated that breast cancer will remain the second leading cause of death 
after heart disease in the United States. 
Breast cancer occurs when cells in the lining of the milk duct or the lobules that provide milk to the 
duct undergo a series of mutations. These mutations may take several years to develop. The cause of 
these cellular mutations is still under investigation but may be attributed to several factors including 
aging, family history, carcinogens, poor diet, smoking and excessive drinking. Breast cancer cells 
proliferate uncontrollably and may induce metastasis, which is the main cause of death associated with 
breast cancer [2,3]. Metastasis is the complex process in which cancer cells spread out to other parts of 
the body through the bloodstream or the lymphatic system [4]. Tumor microenvironments play an 
important role in the regulation of metastasis [5–8]. The communication between cancer cells and their 
microenvironments triggers cancer cells to break away from the original tumor and invade other areas 
of the body [9–12]. Cell migration and invasion play a pivotal role in the onset of metastasis. Current 
treatments focused on eradicating metastatic cancer cells include systemic therapy (e.g., 
chemotherapy, hormonal therapy, biological therapy) and local therapy (e.g., surgery, mastectomy, 
lumpectomy). While advances in science and technology have aided in providing improved treatments 
to reduce the number of deaths caused by breast cancer, it remains a huge challenge to fully understand 
the mechanisms of cell migration and invasion, and to completely eliminate cancer cells to prevent 
disease recurrence and metastasis. The engineering of unique tumor microenvironments in vitro which 
can manipulate the proliferation and migration of metastatic breast cancer cells may permit enhanced 
study of cancer metastasis. Consequently, this could provide greater insight into the decision-making 
processes regarding the growth, migration, and invasion of cancer cells and its subsequent prevention. 
With the advancement of embryonic stem (ES) cell technology, the use of bioengineered ES cell 
microenvironments provides an ideal platform to study and understand the inhibition along with the 
metastatic potential of invasive breast cancer cells in vitro. Firstly, the undifferentiated ES cell 
microenvironment represents a unique microenvironment to counteract tumorigenesis and metastasis. 
Prior studies indicate that cancer cells generally interact with a microenvironment that facilitates 
plasticity, tumorigenicity and metastasis  [5,9,13–15],  while ES cells sustain a microenvironment 
regulating self-renewal and differentiation [16,17]. The embryonic microenvironment has the potential 
to reverse the malignancy state of tumors as it might consist of environmental factors that have the 
ability to reprogram cancer cells into a less invasive phenotype [18–25]. Furthermore, research has 
indicated that the undifferentiated ES cell microenvironment reduces cancer cell growth, as opposed 
to, the differentiated microenvironment which increases growth [26]. Secondly, since breast cancer 
cells are believed to originate from mutations caused by rapidly dividing stem cells, attempts to restore 
the mutated tumor microenvironment with a bioengineered embryonic microenvironment may 
overturn cancer cell progression. Thirdly, the creation of ES cell microenvironments may help identify Int. J. Mol. Sci. 2011, 12                      
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anti-tumor and/or anti-metastasis factors through the study of interactions of ES cells and metastatic 
breast cancer cells. In addition to discovering the ability of the ES cell microenvironment to halt 
cancer cell growth and migration, the co-culture of ES cells and breast cancer cells would also offer 
the recreation of in vitro breast cancer models for mechanism studies and drug screening. 
In this review, we will summarize findings  regarding the utilization of the embryonic 
microenvironment in vivo and in vitro to understand and inhibit cancer metastasis. A brief discussion 
of breast cancer cell and embryonic stem cell characteristics will be included. Lastly, we will discuss 
the recent discovery within our own laboratory that bioengineered 3D embryonic microenvironments 
inhibit the proliferation and migration of metastatic breast cancer cells. Together, the study of ES  
cell-cancer cell interactions in a bioengineered system will provide valuable insight into the 
fundamental understanding of tumor progression and therapeutic development for metastatic diseases. 
2. Characteristics of Breast Cancer Cells and Tumor Microenvironments 
2.1. Uncontrolled Tumor Growth 
Excessive cancer cell proliferation is due to the overexpression of proteins produced by oncogenes, 
which are created via the mutation of normal proto-oncogenes and tumor suppressor genes. Mutated 
cells do not respond to typical cell cycle regulation mechanisms such as programmable cell death, 
known as apoptosis, leading to the overgrowth of damaged cells. For instance, proto-oncogenes as well 
as cell surface receptors, erb-B2 and epidermal growth factor receptor (EGFR) are normally activated 
after the binding of the EGF ligand to induce normal cell proliferation. The binding subsequently 
induces erb-B2 and EGFR endocytosis and regulates the normal intracellular signaling cascade. In 
contrast, the erb-B2 and EGFR oncogenes, which are categorized under the receptor tyrosine kinases 
family, send signals to promote cancer cell division without having to bind to any growth factors 
resulting in dramatic, uncontrolled growth of tumor cells. In addition, the overexpression of EGFR  
and erb-B2 oncogenes stimulates invasiveness of breast cancer cells [27].  
Other important mutant proto-oncogenes that are responsible for breast cancer cell proliferation and 
differentiation include cyclins, cyclin dependent kinases (CDK), the tyrosine kinase family of growth 
factor receptors, and the c-myc oncogene [28]. The mutated/transformed tumor suppressor genes that 
accelerate the breast cancer cell growth include p53, retinoblastoma (Rb) gene, BRCA1 and BRCA2, 
PTEN, ATM, Brush-1, Maspin and nm231 [29]. These previously mentioned oncogenes are just a few 
examples of impaired genes in breast cancer as there are over thousands of reported deviations within 
the genome [30–32]. 
2.2. Metastasis 
In order for metastasis to occur, breast cancer cells must first undergo several critical cascades 
influenced by genetic or epigenetic modifications.  Initially, breast cancer cells proliferate rapidly 
enhancing their aggressiveness due to the presence of oncogenes. The extracellular matrix (ECM) 
surrounding breast cancer cells,  is  subsequently degraded by matrix metalloproteases (MMPs) 
allowing cells to migrate and invade the stroma. MMPs are a family of proteinases that regulate cell 
signaling to promote growth, inflammation,  and/or angiogenesis  [33].  In addition to MMPs, the Int. J. Mol. Sci. 2011, 12                      
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delocalization of cancer cells from the primary tumor is also caused by the decrement in the expression 
of cell adhesion proteins, for example, CD44 [34], E-cadherins [35], integrin [36], and vimentin [35]. 
During this phase, cancer cells in the primary tumor are transitioning in what is referred to  as 
epithelial-mesenchymal transition (EMT), which is essentially a program that induces cells to be 
highly mobilized in order to migrate away  [37,38].  Breast cancer cell migration is guided by 
chemokines through the paracrine loop, such as CCL18 [39], CCR4 [40], CCL25 [41], CXCL14 and 
CXCL15 [42]. Additionally, invasive breast cancer cells, MDA-MB-231, undergo metastasis in vivo 
based on the communication between their secreted factors, colony stimulating factor-1 (CSF-1) and 
EGF, which are growth factors released by surrounding macrophages  [43].  Transcription factors 
involved during the EMT state of breast cancer include Snail, Slug, Twist, Six1, Lbx1, and ZEB [44]. 
The known signaling pathways that influence the behavior of these transcription factors during EMT 
are TGF-β, Wnt/β-catenin, and Msx2/Cripto pathways [45]. Moreover, tumor necrosis factor-alpha 
(TNF-α) is involved in the promotion of metastasis. TNF-α is a transmembrane protein that stimulates 
tumor proliferation and survival via NF-κB-, PKCα- and AP-1-dependent signaling pathways [46]. 
The morphological processes of a cancer cell during the  EMT phase are termed lamellipodia, 
filopodia and invadopodia, and are governed by a very active actin-cytoskeletal component and a high 
concentration of proteases [47,48]. Briefly, lamellipodia are wide protrusions located at the edge of 
cells during motility, while filopodia are long and thin actin filaments protruding several micrometers 
ahead beyond the lamellipodia coverage. Invadopodia are structures possessed by cells that are highly 
enriched in actin filaments and are responsible for degrading the ECM to drive cancer cell invasion. One 
critical actin-binding protein that facilitates normal cellular migration is Profilin1. It has been reported 
that the down-regulation of this protein promotes motility in breast cancer cells (MD-MB-231) through 
the increased amount of lamellipodia [49,50]. Another well-known actin skeletal protein that drives 
metastasis is Mena. Mena is upregulated and highly expressed in invasive breast cancer cells [51]. 
Regarding breast cancer motility during metastasis, two types of cancer cell migration exist and are 
termed amoeboid migration and collective cell migration [52]. Amoeboid migration is defined as the 
movement of cells that have reduced focal adhesions and maintained high flexibility. Collective cell 
migration refers to the cell movement while in contact with neighboring cells. Following the 
migration, highly motile breast cancer cells will move directionally towards blood vessels and enter 
the blood or lymphatic vasculature via intravasation [53]. As a result the invasive breast cancer cells 
migrate out of the primary tumor via blood vessels and reach a secondary organ in the body via 
extravasation, creating a new metastatic site. 
2.3. Tumor Microenvironment 
Breast cancer cell growth and behavior that promotes  metastasis  is  mainly influenced by the 
complex and highly structured microenvironment [15,54–59]. The tumor microenvironment consists of 
soluble factors, ECM and neighboring cells [8,60]. Soluble factors include encircling cytokines and 
growth factors that have the potential to guide cells toward a malignant state. MMPs exemplify soluble 
factors that modulate the tumor microenvironment [33]. There are several types of MMPs that work 
synergistically to induce breast cancer metastasis  [61].  MMPs  function  by cleaving cell surface 
receptors, which in turn, detaches the bound ECM. Consequently, this process leads to the degradation Int. J. Mol. Sci. 2011, 12                      
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of the ECM that permits breast cancer cells to migrate and intravasate. Prior studies indicate that 
MMP-1, -2, -8, -9 -10, -11, -12, -13, -15, -19, -23, -24, -27 and -28 promote breast cancer development 
and tumor progression  [62].  In particular, MMP-1,  -9, and -13 are strongly correlated with the 
incidence of breast cancer metastasis and are potential markers for poor prognosis of invasive breast 
cancer  [63–66].  The activity of MMPs can be inhibited by endogenous tissue inhibitor of 
metalloproteinases (TIMPs), including TIMP-1, TIMP-2, TIMP-3, and TIMP-4 [67]. Among these 
inhibitors, TIMP-1 inhibits MMP-1, -3, and -9 more effectively than TIMP-2 [68–70], while all types 
of TIMPs are able to inhibit active MMP-13 [71,72]. Another critical soluble factor that is highly 
expressed in the tumor microenvironment is EGF [73]. EGF stimulates the proliferation of breast 
cancer cells by binding to EGFR which is one of the oncogenes of breast cancer. EGF also displays 
chemotactic properties in facilitating cell migration towards metastasis [74]. Two additional examples 
of growth factors associated with the development of metastatic breast cancer include fibroblast 
growth factors (FGF) [75] and transforming growth factor-β (TGF-β) [76]. 
Within  the  tumor microenvironment, the  ECM constitutes the basement membrane and the 
interstitial matrix, providing a cushion for cells to grow. The mechanical properties of cancer cells, 
dictated by external exertion  from  the surrounding microenvironment,  impact  the degree of 
invasiveness as well [77]. The ECM is defined as connective tissues comprised of fibrous proteins and 
polysaccharides. The bidirectional communication and interaction between cancer cells and the ECM 
contributes to the progression of metastasis. Major components of the ECM in the basement membrane 
include collagen, elastin, laminin and fibronectin. The interstitial matrix consists of polysaccharides 
such as proteoglycans and hyaluronic acid. Breast cancer cells are attached to the ECM and other cells 
via transmembrane glycoproteins such as integrin and E-cadherin. The loss of these proteins is one of 
the hallmarks of cancer metastasis  [78].  Reportedly,  the reduced expression  of these proteins is 
associated with other contributing factors in the tumor microenvironment such as TGF-β [79] and 
MMPs [80]. 
Another critical factor in the tumor microenvironment is neighboring cells. Fibroblasts, 
myoepithelial cells, adipocytes, endothelial cells, and leukocytes are examples of cells that surround 
breast cancer cells. In addition to providing scaffolds for cancer cells to grow, these cells secrete 
signals, cytokines, and growth factors that may increase the malignancy of cancer cells [81]. The term 
tumor microenvironment of metastasis (TMEM) coined by Robinson et al. includes three critical cells 
in the tumor microenvironment: an invasive carcinoma cell, a macrophage, and an endothelial cell. 
The researchers discovered that the density of TMEM was higher in metastatic patients as compared to 
primary breast cancer patients  [82].  A study by Yizraeli et al. reported that  following  the  direct 
application of an electric field to induce apoptosis in breast cancer cells, the apoptotic event was 
delayed when these cells were co-cultured with fibroblasts as opposed to breast cancer cells alone [83]. 
This result illustrates the importance of neighboring cells, fibroblasts in this case, in governing tumor 
malignancy. Furthermore, considering the fact that surrounding cells play a significant role in directing 
metastasis, in vitro co-culture of breast cancer cells with other cells may increase understanding of 
tumorigenesis. For instance, MCF-7 breast cancer cell proliferation was inhibited when co-cultured 
with preadipocytes [84]. Additionally, breast cancer cells cultured three dimensionally in the presence 
of normal breast fibroblasts displayed reversion of tumor phenotype [85] and formation of ductal 
structures [86]. Several studies have also revealed the enhancement of tumorigenicity of breast cancer Int. J. Mol. Sci. 2011, 12                      
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cells when they were co-cultured with adipocytes [87], benign mammary epithelial cells [88], bone 
marrow stem cells [89] and endothelial cells [90]. Reconstructing a human breast cancer model is 
indeed crucial and theoretically  more physiologically relevant with respect to attaining  proper 
understanding of cell-cell interaction related to metastasis. 
2.4. Reprogramming Breast Cancer Cells 
It is possible to halt breast cancer cell progression under certain conditions. Firstly, it may be 
accomplished through the arrest of cell proliferative capacity, termed cellular senescence [91], which 
involves the shortening of telomeres [92] or p53 activation [93]. Secondly, blocking of oncogenes 
contained in breast cancer cells and their microenvironment may facilitate the overturn of cell 
proliferation and migration. One great example is the treatment of Trastuzumab, a humanized   
anti-HER2/neu antibody, to inhibit erb-B2 tyrosine kinase receptor (TKR) oncogenic activity [94]. 
Another possible blocking mechanism is the arrest of MMP activity. Since MMPs play a critical role 
in tumor invasion and metastasis through the degradation of the ECM, impeding the enzyme may 
reduce tumorigenesis. The major inhibitors of MMPs include TIMP1 and TIMP2 [95]. Furthermore, 
blocking the growth factor receptors involved in promoting breast cancer aggressiveness may also 
contribute to the anti-proliferative capability of cells [96]. The obstruction of the receptor involved in 
invadopodia formation, platelet derived growth factor receptor (PDGFR),  through its transcription 
factor, Twist1, prevents breast cancer metastasis [97]. Additionally, targeting cell adhesion proteins 
such as integrin by creating its antagonist is a promising anti-cancer therapeutic strategy [98]. The 
blocking of certain oncogenes and signaling pathways may induce apoptosis in breast cancer cells as 
well [99], leading to potential alternatives in breast cancer therapy. 
Considering the fact that the  tumor microenvironment has emerged as  a significant and vital 
component that drives metastasis, targeting the breast cancer cell microenvironment may be one of the 
potential solutions in reprogramming breast cancer invasiveness  [100].  In particular, this review 
focuses on utilizing the embryonic microenvironment to replace the tumor microenvironment in order 
to reprogram cancer cells into a less invasive phenotype, thereby, reducing the instances of metastasis. 
3. Characteristics of Embryonic Stem Cells and Microenvironments 
3.1. Self-Renewal and Pluripotency of Embryonic Stem Cells 
ES cells originate from the inner cell mass of the blastocyst which forms a few days after the 
fertilization process. ES cells are taken from the blastocyst and cultured in the lab in vitro. ES cells 
have the capability to self-renew indefinitely making them a significant source of cell regeneration. 
Additionally, these cells are unique in that they are pluripotent meaning they have the potential to 
differentiate into all cell types found within  the  three germ layersthe ectoderm,  mesoderm and 
endoderm. These remarkable and unique properties make ES cells valuable in areas such as 
regenerative medicine, drug discovery, and diagnostics. 
The indefinite self-renewal of ES cells is controlled by several proteins and genes. Transcription 
factors  Oct4, Nanog and Sox2 play a major role in guiding ES cells to proliferate  [101].  The 
downregulation of these genes causes ES cells to undergo differentiation [102]. In this article, we will Int. J. Mol. Sci. 2011, 12                      
 
7668 
focus on the microenvironment of undifferentiated ES cells as they restrict tumor cell growth and 
metastasis, as opposed to  differentiated ES cells which  promote the growth of tumor cells  [26]. 
Interestingly, Oct4, which is a potent canonical marker for ES cell pluripotency, is downregulated 
during the EMT phase of breast cancer cells [103]. This particular finding may also indicate that the 
loss of Oct4 expression in differentiated ES cells creates  a microenvironment favorable to 
tumorigenesis. In the presence of leukemia inhibitory factor (LIF), mouse ES cells hypothetically 
release certain chemokines/cytokines and growth factors, including interleukin (IL)-1α, IL-10, IL-11, 
macrophage-colony stimulating factor (M-CSF), oncostatin M, stem cell factor (SCF), VEGF, CXCL1, 
2, 6, and 10, CCL2, 4, 7, and 22, CD 40, MMP-9, and TIMP-1 (listed in Table 1) [104]. These 
cytokines and growth factors provide signals for ES cells to remain alive and retain the capacity for 
self-renewal and pluripotency. Additionally, the effects of these soluble factors on breast cancer cells are 
listed in table 1. Although comparable factors are present, breast cancer cells contain mutated genes that 
lead to under- or overexpression of these chemokines/cytokines and growth factors. Therefore, different 
levels are present in the tumor microenvironment compared to the ES cell microenvironment. As shown 
in Table 1, breast cancer cells secrete much higher level of M-CSF, OSM, MIP-2/CXCL-2, MMP-9 and 
TIMP-1 than ES cells, which are factors correlated with tumor metastasis. 
Table 1. Comparable soluble factors secreted by murine embryonic stem (ES) cells and 
breast cancer cells and their effects on the latter cells. 
Name 
Molecular 
Weight 
(kDa) 
C (pg/mL) 
Secreted by 
ES Cells [104] 
C (pg/mL) 
Released by Breast 
Cancer Cells 
Effects on Breast Cancer Cells 
CYTOKINES  20–45       
IL-10  20  +++  ++  Expressed in tumor samples [105] 
and associated with reduced  
disease-free survival [106] 
IL-11  23  ++  +++  Produced by breast cancer  
cells [107] and linked to poor 
survival [108] 
IL-1α  33  ++  +++   Expressed in poorly differentiated, 
ERα-negative tumors [109] 
M-CSF  18.5  +++  ++++  CSF-1/CSF-1R autocrine signaling 
contributed to the invasion 
phenotype of breast cancer [42] 
OSM 
(Oncostatin M) 
28  ++  ++++++   0.1–100 ng/mL OSM: inhibited 
proliferation/changed cell 
morphology [110,111];  
20–50 ng/mL OSM: increased 
invasive potential [112] 
SCF 
(Stem Cell 
Factor) 
45  ++    High expression of SCF and SCF-R 
in normal mammary samples and 
low in invasive tumors [113]; 
enhanced activation of the MAPK 
and PI3K pathways [114] Int. J. Mol. Sci. 2011, 12                      
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Table 1. Cont. 
3.2. Embryonic Microenvironments 
The embryonic microenvironment plays a crucial role in determining the cellular fate of embryonic 
stem cells: whether to direct cells to self-renew, proliferate, differentiate, remain inactive or experience 
death. The general components of the embryonic microenvironment also include soluble factors, ECM 
and neighboring cells.  The  ECM regulates  ES cell signaling in a spatially-patterned fashion by 
providing structural support to cells, integrating complex cellular signals,  and controlling the 
distribution and activation of growth factors. To mimic the ES cell microenvironment, mouse [125] 
and human embryonic fibroblasts [126] are initially incorporated as a feeder layer to maintain ES cells 
in  an  undifferentiated state. Matrigel [127]  and ECM proteins [128]  are  employed to support the 
maintenance of ES cell pluripotency in feeder layer-free cultures. Soluble factors for self-renewal of 
ES cells include LIF for mouse ES cells [129] and basic fibroblast growth factor (bFGF) for human ES 
cells  [130]. Additionally, insulin growth factor-receptor (IGF-R), erb-B2 receptor signaling,  and 
activin-A are required to maintain human ES cell pluripotency [131]. 
Name 
Molecular 
Weight 
(kDa) 
C (pg/mL) 
Secreted by 
ES Cells [104] 
C (pg/mL) 
Released by Breast 
Cancer Cells 
Effects on Breast Cancer Cells 
CYTOKINES  20–45       
VEGF  42  +++  +++  Angiogenic effect [115] 
CHEMOKINES  <13       
GCP-2/CXCL6  8  ++    Upregulated in breast cancer  
cells [116] 
IP-10/CXCL10  10  +++  +++  Promote metastasis in a murine 
model [117] 
KC/GROα/CXCL
1 
11.3  +++    Angiogenic effect [118] 
MCP-1/CCL2  11–13  +++  +++  Highly expressed in breast  
tumor [119] 
MCP-3/CCL7  11  ++    Overexpressed in breast carcinoma 
patients [120] 
MDC/CCL22  8.1  ++    Involved in breast cancer lung 
metastasis [121] 
MIP-1β/CCL4  7.8  ++  +++  Downregulated in breast carcinoma 
patients [120] 
MIP-2/CXCL2  6  +  +++  Highly expressed in bone metastatic 
breast cancer [122] 
OTHERS  >29       
CD 40  43  ++    Anti-tumor activity in breast cancer 
cells [123] 
MMP-9  90  ++++  +++++  Overexpressed in breast cancer  
cells [64] 
TIMP-1  29  +++++  ++++++  Inhibits breast cancer cell  
apoptosis [124] Int. J. Mol. Sci. 2011, 12                      
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3.3. Bioengineering Embryonic Stem Cell Microenvironments 
The microenvironments of ES cells play a fundamental role in providing cells with appropriate 
signaling to induce cell proliferation, differentiation or death. The bioengineering of ES cell 
microenvironments in vitro may permit the emulation of the heterogeneous and highly complex nature 
of ES cells, enabling a clearer understanding of stem cell fate decision. In order to recapitulate the native 
stem cell niche, researchers have exploited several bioengineering methods. For example, to replicate  
the ECM, various types of scaffolds composed of naturally and synthetically derived polymers, or both,  
have been engineered. Naturally derived polymers include alginate, gelatin, Matrigel and chitosan. 
Poly(L-lactic acid) (PLLA), poly(ethylene glycol) (PEG) and poly(ε-caprolactone) (PCL) are examples 
of synthetic polymers. Researchers have demonstrated that human ES cell pluripotency is maintained 
when the ES cells are cultured in a 3D hyaluronic acid [132], alginate [133,134], or chitosan scaffold [135]. 
Specifically, our lab has reported that mouse ES cells encapsulated inside aqueous alginate hydrogel 
microstrands prefer differentiation towards either a mesoderm or endoderm lineage [136]. A study by 
Peng S. et al. revealed that mouse ES cells cultured on gelatin induces  cell differentiation into 
trophectoderm  [137].  Furthermore, the application of synthetic polymers within the field of 
nanotechnology for stem cell culture is mainly the fabrication of nanofibers. For instance, human ES 
cells cultured on nanofibrous scaffolds exhibit a greater affinity for hepatocyte [138], neuronal [139] 
and osteogenic differentiation [140,141]. Additionally, mouse ES cells seeded on PCL nanofibers 
undergo directed differentiation into adipocyte [142] and neural lineages [143]. It is also worth noting 
that the main purpose of these synthetic nanofibrous scaffolds is to guide stem cell differentiation. 
Altogether, these findings are indicative of the manners in which different types of engineered 
biomaterial scaffolds can produce varying stem cell self-renewal or differentiation potentials. In 
addition to scaffolds, self-renewal of ES cells is maintained by incorporation of growth factors such as 
LIF [129] or bFGF [130], which will inherently induce greater cell expansion. 
To closely imitate the specific types of biomolecules surrounding ES cells, the field of 
nanotechnology offers a potential solution through the creation of nanoparticles capable of delivering 
the necessary growth factors to stimulate stem cell proliferation or differentiation. For example, Tran 
and coworkers studied the influence of nanoparticles on mouse ES cell viability and differentiated 
morphology and discovered that mouse ES cells differentiate into different cell types, for example, 
fibroblast-like cells or embryoid bodies, depending on the concentration of the polystyrene 
nanoparticles in which they are exposed [141]. In reference to the neighboring cells of ES cells, the 
emergence of cellular patterning technology has yielded potential techniques for taking advantage of 
bioengineered ES cell microenvironments comprised of manufactured cell-cell interactions  [144]. 
Specifically, this technology contributes to co-culture feasibility through the creation of a combinatorial 
library of cells that ordinarily exist in vivo. In addition, the possibility of investigating the influences of 
ES cell location and spatial proximity in relation to other types of cells has become tangible. Most 
importantly, mouse ES cells maintain their pluripotency after laser direct-write patterning and this 
particular finding reveals the mechanisms for exploitation of this technology in order to understand 
cellular interactions between ES cells and breast cancer cells. Int. J. Mol. Sci. 2011, 12                      
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4. Embryonic Microenvironment and Cancer 
4.1. The Importance of Embryonic Microenvironments in Inhibiting Tumorigenesis 
The importance of the embryonic microenvironment in cancer progression and metastasis has been 
demonstrated  in zebrafish, chick and mouse embryonic models  [26,145–147].  Mintz & Illmensee 
performed the initial study implying  that  exposure to the  mouse embryonic microenvironment 
reprograms teratocarcinoma cells into cells capable of differentiating into normal cells [148]. Pierce et al. 
showed that embryonic microenvironments inhibit the tumorigenicity of embryonal carcinoma cancer 
cells  [149].  Hendrix and colleagues performed multiple studies demonstrating that embryonic 
microenvironments prevent human melanoma cells from tumorigenesis  after  implantation into  the 
embryo of zebrafish [150] or revert the metastatic melanoma phenotype to its cell type of origin in an 
embryonic chick model  [24].  The capability  of the embryonic microenvironment to  inhibit 
tumorigenesis and reprogram metastatic cancer cells to a less aggressive phenotype was confirmed 
using an in vitro mouse embryo model [151] and intrauterine transplantation mouse model [152], 
respectively. These studies reveal the uniqueness of the embryonic microenvironment in halting 
tumorigenicity. For example, Patton et al. observed enhanced tumor growth when cancer cells were 
implanted in adult zebrafish as opposed to an embryonic microenvironment [153]. These findings are 
supported by Kasemeier-Kulesa  et al., who reprogrammed human multipotent tumor cells into a 
benign phenotype when transplanted in a neural crest chick microenvironment [147]. All this evidence 
demonstrates  the capacity  of  the  embryonic microenvironment to  either delay or reverse 
tumorigenesis, suggesting that embryonic microenvironments might contain factors that could inhibit 
cancer growth and metastasis. 
4.2. Convergence of Tumorigenic and Embryonic Signaling Pathways 
Embryonic signaling pathways such as Notch, Hedgehog (Hh), Wnt, and TGF-β, are responsible for 
initiating and driving  EMT during embryogenesis  [154,155].  These pathways are imperative in 
maintaining  the highly-regulated  ES cell processes of proliferation, differentiation, movement and 
polarity.  Tumorigenic and embryonic signaling pathways cross paths  during  the course of EMT. 
Additionally, deregulation of embryonic signaling pathways is found in breast, pancreas, and lung 
tumors [45]. 
TGF-β and Wnt/β-catenin signaling pathways are misexpressed in breast cancer and associated with 
poor clinical outcomes [37,38]. The TGF-β pathway activates Notch, Hh and Wnt signaling and plays 
an important role in the process of EMT, embryogenesis and tumorigenesis. Two main branches of the 
TGF-β signaling pathway are SMAD1/5/8 and SMAD 2/3. The former branch is mediated by the 
binding of BMP or GDF ligands to TGF-β receptors ALK1, 2, 3, and 6, whereas, the latter branch is 
mediated by the binding of Activin and Nodal ligands to TGF-β receptors ALK4, 5, and 7 (Figure 1). 
The activation of TGF-β signaling triggers the phosphorylation of SMADs which subsequently form 
complexes with SMAD that translocate to the nucleus and regulate gene expression. In this way, the 
induction of EMT via cell signaling proteins, SMAD3 and SMAD4,  is activated by the  TGF-β 
pathway.  Mutations  and  deregulation of TGF-β  receptors  leading to  inactivation of SMAD4 are 
observed  in  various cancers.  Examples of  TGF-β  inhibitors  include Lefty A, Lefty B, Gremlin, Int. J. Mol. Sci. 2011, 12                      
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Cerberus, Follistatin, and Chordin. The mechanism of Wnt signaling involves the binding of a Wnt 
ligand to the FRIZZLED receptor to activate Dishelved (Dsh) protein (Figure 1). Dsh inhibits GSK-3 
which is responsible for β-catenin degradation. Upon Wnt activation, β-catenin accumulates in the 
cytoplasm and translocates to the nucleus where it interacts with the  transcriptional factor T-cell 
Factor/Lymphocyte Enhancing Binding Factor (Tcf/Lef) [155]. In tumors, Wnt signaling is active and 
thus stabilizes β-catenin, whose binding to Tcf/Lef activates oncogenes of c-myc and cyclin D1 and 
stimulates tumor cell proliferation. Documented inhibitors of Wnt signaling include Dkk1, 3, sFRP, 
WIF-1 and Cerberus. 
Figure 1. Schematics of TGF-β and Wnt signaling pathways that show the cross-path in 
tumor and ES cell microenvironments. ES cells can secrete inhibitors of TGF-β and Wnt to 
regulate the normal embryonic program. 
 
As previously mentioned, embryonic  signaling pathways are tightly controlled in the ES cell 
microenvironment. Mutations occur within tumor and stromal cells in a tumor microenvironment. 
Breast tumor cells and ES cells secrete cytokines and chemokines to their microenvironment, however, 
breast cancer cells secrete a significantly higher level of soluble factors, which is correlated with tumor 
metastasis (e.g., M-CSF, OSM, MIP-2/CXCL-2, MMP-9, TIMP-1). Undifferentiated ES cells could 
secrete Lefty A, Lefty B, Gremlin, Cerberus, etc., which are inhibitors of TGF-β and Wnt. Tumorigenic 
and embryonic microenvironments  converge via TGF-β  and  Wnt  signaling  pathways.  However, 
deregulation of embryonic signaling pathways occurs and critical inhibitors to regulate normal 
embryonic pathways are missing in a tumor microenvironment. The ES cell microenvironments have 
great potential to supply critical signaling molecules and reprogram the abnormal embryonic signaling 
pathway in tumors.  Int. J. Mol. Sci. 2011, 12                      
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4.3. Breast Cancer Stem Cells and Embryonic Stem Cell Microenvironment 
The recurrence of breast cancer accompanied with the manifestation of metastasis may be attributed 
to the presence of breast cancer stem cells (CSCs) within the tumor. Breast CSCs are a small subset of 
cells coexisting within the breast cancer cell population that have the ability to self-renew and to 
differentiate into heterogeneous cancer cells. The origin of breast CSCs is not fully understood but is 
thought to arise from a mutation that occurs during continuous stem cell division and replication.  
Al Hajj et al.  are  the first researchers to identify a subset of breast CSCs isolated directly from  
patients [156]. Their study demonstrates that only a small subset of CD44
+/CD24
− breast cancer cells 
is capable of driving carcinogenesis and possesses the ability to self-renew and to generate multiple 
cancer cell types. In addition to the CD44
+/CD24
− phenotype, other prominent biomarkers of breast 
CSCs include aldehyde hydrogenase (ADH)1 [157], CD49f, CD29, and CD133 [158]. Breast CSCs are 
also highly regulated by their complex and dynamic niche. Bidirectional communication between breast 
CSCs and their surroundings, such as neighboring cells (fibroblasts, endothelial cells, macrophages, 
mesenchymal stem cells,  etc.) and soluble molecules (CXCL12, IL-6, IL-8,  etc.) greatly influences 
cellular development.  For instance, the cytokines IL-6 and CXCL7 are secreted from nearby 
mesenchymal stem cells  resulting in the self-renewal of breast  CSCs via the activation of 
STAT3/NFκB signaling [159]. Targeting the breast CSC niche may provide an alternative method to 
eradicate the source of breast cancer in order to prevent disease recurrence or metastasis [160,161]. 
Several excellent review papers on breast CSCs are referenced for readers interested in obtaining 
greater detail regarding this subject [45,162,163]. 
Wong et al. elucidated an important aspect in reference to the relationship between breast CSCs and 
the ES cell microenvironment and reported that the ES cell-like gene module is activated in diverse 
human epithelial cancers, including liver, breast, prostate, gastric and lung cancer, where identification 
of an ESC-like signature is a powerful predictor of metastasis and death. In particular, c-Myc, rather 
than other oncogenes, is sufficient to reactivate the ES cell-like transcriptional program in normal and 
cancer cells [164]. Alternatively, Somervaille et al. implemented a leukemia stem cell model system to 
study the similarity of CSCs and ES cells. The researchers illustrated that CSCs share transcriptional 
regulators of self-renewal with ES cells, such as Hmgb3, Cbx5, Mtf2, and Orc21 [165]. However, this 
ES cell-like state in CSCs is not mediated by the upstream regulators Nanog, Oct4, or Sox2, which are 
essential transcription factors for maintaining the pluripotency of ES cells. Furthermore, it is predicted 
that the poor prognosis of human malignancies is caused by an inappropriate expression of upstream 
regulators linked with a down-stream ES-like program for aberrant self-renewal of ESCs. Therefore, ES 
cells self-renew in a highly regulated manner, whereas CSCs self-renew in a poorly controlled manner. 
This study supports the notion that restoring the normal niche of the ES cell microenvironment may 
cause breast CSCs to convert to a benign phenotype. 
Breast CSCs also employ embryonic  signaling  pathways in order to commence EMT for the 
occurrence of metastasis. However, unlike embryogenesis, metastasis is driven by transformation of 
embryonic pathways. Considering the heavy involvement of these altered embryonic pathways in 
driving metastasis, it is clear that targeting them is a promising approach in treating breast cancer. We 
hope that replacing the breast CSC microenvironments with a normal ES cell niche may alleviate the 
deregulation of embryonic pathways, which in turn will restrict metastatic disease. Int. J. Mol. Sci. 2011, 12                      
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4.4. Reprogramming of Metastatic Cancer Cells Using ES Cell-Conditioned Microenvironments 
A  state of the art technique for  examining  the  potential  ability  of  ES  cell-conditioned 
microenvironments  to  cease  cancer cell growth involves  hES cell-conditioned Matrigel and was 
performed by Hendrix’s group. This research  demonstrated  that hES cell-conditioned Matrigel 
reprograms  metastatic melanoma cells to a less aggressive phenotype and significantly inhibits 
invasiveness and tumorigenesis [166]. Most of these in vivo and in vitro studies focus on melanoma 
cells.  At this point, only two studies have  investigated the effects  of human ES cell-conditioned 
Matrigels on human breast cancer cells. Postovit et al. showed that cancer cells overexpress Nodal 
genes, the embryonic morphogen expressed in hES cells. Basically, these genes are responsible for the 
maintenance of pluripotency in ES cells and tumorigenesis in cancer cells. The expression of these 
genes  is regulated by Lefty, an inhibitor of the  Nodal signaling pathway. However, Lefty is  not 
expressed in breast cancer cells or their microenvironments. As shown in Figure 1, exposure of cancer 
cells to the ES cell-conditioned Matrigel (containing Lefty) could suppress Nodal gene expression in 
cancer cells leading to apoptosis,  which  is  significant because recombinant Lefty is  unable to 
downregulate Nodal  [23].  This finding is directly attributed to the fact that the ES cell 
microenvironment-derived Lefty was glycosylated and more physiologically active in comparison to 
recombinant Lefty.  In addition to Nodal knock-down, they also observed  the down regulation of   
VE-Cadherin (a tumor angiogenesis marker) after the exposure of human melanoma cells to hES  
cell-conditioned Matrigel [167]. Subsequent studies performed by this group have offered additional 
factors  within  the  human ES cell microenvironment that potentially  contribute  to epigenetic 
reprogramming of metastatic tumor cells such as DNA methylation and microRNA regulation [22]. 
Kim et al. further clarified the implementation of a mouse ES-conditioned Matrigel to inhibit human 
melanoma cells. Their findings highlighted the discovery of  an important factor in the  ES  cell 
microenvironment responsible for halting cancer cell proliferation, Gremlin. Gremlin is an antagonist of 
bone morphogenetic protein 4 (BMP4) that regulates stem cell expansion and differentiation. As shown 
in Figure 1, the presence of Gremlin induces cellular senescence in melanoma cancer cells [25]. Another 
study by Ben-Porath et al. revealed that poorly differentiated tumor cells consist of genes that are highly 
expressed in human ES cells such as Nanog, Oct4, Sox2 and c-myc as compared to well differentiated 
tumor cells [168]. The relationship between human ES cell conditioned medium and human epithelial, 
ovarian, prostate and breast cancer cell proliferation was assessed by Giuffrida et al. [21]. In their 
study, cancer cell proliferation decreases  after exposure to human ES cell-conditioned media as 
compared to the controls containing mouse fibroblast conditioned media and normal cancer cell media. 
Dilution studies demonstrated that depletion of nutrients in human ES cell-conditioned medium does 
not contribute to the arrest of cancer cell proliferation [21]. This study confirms that hES cells secrete 
factors smaller than 10 kD which plays a major role in inhibiting cell proliferation and terminating the 
cell cycle. Referring to Table 1, which contains a list of cytokines released from undifferentiated 
murine ES cells, it is apparent that chemokines are factors that typically have molecular weights less 
than 10 kD and play a critical role in inhibiting cancer cell proliferation (Figure 2). These findings 
implicate ES cell-derived active microenvironments as important sources of tumor suppression factors, 
which are summarized in Table 2. Int. J. Mol. Sci. 2011, 12                      
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Figure 2. Schematics of the interactions of embryonic stem (ES) cell microenvironments 
and cancer cells. 
 
Table 2. State of the art research regarding the utilization of embryonic microenvironments 
to understand and inhibit cancer metastasis. 
Embryonic 
Microenvironments 
Cancer Cells  Effects  References 
Zebrafish embryo 
model 
Human metastatic 
melanoma cells 
Support cell survival and division 
with no tumor formation.  
[150] 
Embryonic chick 
model 
Human metastatic 
melanoma cells 
Revert the metastatic phenotype to 
its cell type of origin. 
[24] 
hESC-conditioned 
Matrigel 
Human metastatic 
melanoma cells 
Induce a melanocyte-like 
phenotype and significantly inhibit 
the in vitro invasiveness of cancer 
cells. 
[166] 
hESC-conditioned 
Matrigel 
Human metastatic 
melanoma and 
breast cancer cells 
Decrease Nodal expression and 
inhibit tumorigenesis. 
[23] 
hESC-conditioned 
Matrigel 
Human metastatic 
melanoma cells 
Decrease VE-Cadherin expression.  [167] 
hESC-conditioned 
Matrigel 
Human metastatic 
melanoma cells 
Identify miRNAs up- and  
down- regulated in reprogramming 
of melanoma cells. 
[22] 
mESC-conditioned 
Matrigel 
Human metastatic 
melanoma and 
breast cancer cells 
Inhibit cell proliferation, decrease 
anchorage independence and induce 
senescence. 
[25] Int. J. Mol. Sci. 2011, 12                      
 
7676 
Table 2. Cont. 
Embryonic 
Microenvironments 
Cancer Cells  Effects  References 
hESC-conditioned 
medium 
Human epithelial 
ovarian, prostate, 
and breast cancer 
cells 
Inhibit cell proliferation and cell 
cycle (increased cells in G1 and 
deceased cells in S and G2/M 
phase). 
[21] 
In vitro mouse 
embryo model 
Human melanoma 
cells 
Support the melanoma cell 
migration inside the embryo model 
in a way reminiscent of neural crest 
cells with no tumor growth. 
[151] 
Bioengineered mESC 
microenvironment 
Rat metastatic 
breast cancer cells 
Inhibit the growth and migration of 
breast cancer cells. 
[169] 
4.5. Bioengineered Embryonic Microenvironments for Breast Cancer Research 
Most of the previously described experiments demonstrated “state of the art”  techniques for 
exploring the embryonic microenvironment and were analyzed to determine if it is possible to arrest 
cancer cell proliferation and reprogram metastatic cancer cells using in vivo microenvironments or ES 
cell-conditioned Matrigel.  In addition, the  majority of these  studies  focused on human metastatic 
melanoma cells. The  limited  research  related to the exploitation of in vitro  dynamic  embryonic 
microenvironments in an effort to understand and inhibit breast cancer metastasis prompted further 
investigation. In our lab, we have explored  the possibility of using 3D bioengineered embryonic 
microenvironments consisting of alginate hydrogel and mouse ES cells to examine the possibility of 
dynamically reversing malignant growth and migration of metastatic breast cancer cells. 
Bioengineered 3D in vitro models for studying dynamic ES cell-cancer cell interactions can bridge 
the gap between 2D cell cultures and whole-animal systems. Cancer cells cultured in 3D alginate 
hydrogel are capable of forming multicellular tumor spheroids [170–173]. The 3D microenvironment 
recapitulates the native setting and permits tumorigenesis as compared to 2D [174]. Alginate, obtained 
from cell walls of brown algae, is an anionic polysaccharide that consists of β-D-mannuronate and  
α-L-guluronate residues [175,176]. In the past, it has been broadly utilized in tissue engineering and 
regenerative medicine due to its biocompatibility, as well as, gentle gelling behavior. In addition, the 
ability of alginate to retain a large quantity of water mimics glycosaminoglycans (GAG), which are a 
component of the ECM. [177,178] Analogous to GAG, alginate is a negatively charged polysaccharide 
with a high viscosity that could also provide a good platform and structural integrity to allow for 
smooth cell migration. One method of forming alginate hydrogel is through exposure of the alginate 
solution to divalent cations such as calcium chloride, barium chloride, and zinc chloride. Cells are 
encapsulated in alginate hydrogel by combining them with the alginate solution prior to exposure to 
divalent cations.  Alginate hydrogel  is  further coated with poly-L-lysine to modify  its 
microenvironment from  gelled to aqueous via  a  chelating agent such as sodium citrate. The 
encapsulation technology employing alginate hydrogel has been successfully performed  in  studies 
related to various types of systems such as stem cell differentiation [179–183], pancreatic  islets 
delivery for diabetes treatment [184–187] as well as 3D disease models [188,189]. Int. J. Mol. Sci. 2011, 12                      
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ES cells were encapsulated in alginate hydrogel microbeads via an electrostatic-driven method. The 
cells were allowed  to grow within the microbeads  creating an in vitro  bioengineered embryonic 
microenvironment [169]. ES cells in alginate hydrogels remained in an undifferentiated state, which 
supports their self-renewal and pluripotency. The co-encapsulation of ES cells with metastatic breast 
cancer cells in aqueous alginate microbeads displayed inhibition of tumor formation as opposed to 
encapsulation of breast cancer cells alone. Further studies involved the exposure of alginate hydrogel 
microbeads laden with ES cells to highly invasive breast cancer cells to examine the effects on cancer 
cell proliferation and migration. ES cells were encapsulated in alginate hydrogel microbeads (about 
600 µm in diameter) at initial cell densities of 10
5, 3 × 10
5, 5 × 10
5 and 10
6 cells/mL alginate. The 
corresponding cell numbers in each microbead were 11, 34, 56 and 113 cells, respectively. Only one 
bead containing ES cells was added to metastatic breast cancer cells. Following co-culture for 1–2 days, 
the proliferation levels of metastatic breast cancer cells was examined. We discovered that microbeads 
containing 113 ES cells (equivalent to10
6 cells/mL alginate) displayed the highest level of cancer cell 
proliferation inhibition on day one, while all types of microbeads inhibited cancer cell proliferation by 
day two. Therefore, we employed the initial cell density of 10
6 cells/mL alginate for all future studies. 
One, two, five or ten microbeads containing ES cells were co-cultured with metastatic breast cancer 
cells.  After two days of cultivation, five microbeads containing the 113 cells/bead exhibited the 
maximum inhibitory effect on the proliferation of metastatic breast cancer cells. The inhibition rate of 
cell proliferation was over 90%.  In particular, the migration of cancer cells was monitored and 
analyzed using image J software in the absence or presence of ES cells or NIH 3T3 fibroblasts. To 
quantify the speed of cell migration, the average velocity was calculated as the mean of all the values 
of velocity for an individual cell during a 4 hour imaging course. Compared to the control group 
(metastatic breast cancer cells alone), ES cells in hydrogel significantly restricted the growth and 
migration of metastatic breast cancer cells while hydrogel microbeads containing NIH 3T3 fibroblasts 
did not influence these two factors significantly (Figure 3). Based on the results obtained through the 
measurement of breast cancer cell proliferation and quantification of cell migration after the co-culture, 
we  conclude  that mouse ES cells encapsulated in alginate hydrogel microbeads may have secreted 
soluble factors that inhibit metastatic breast cancer cell growth and migration [169]. This bioengineered 
embryonic microenvironment provides a new avenue for identifying anti-tumor/anti-metastasis factors to 
restrict the proliferative capacity and metastatic potential of tumor cells. Elucidation of key components 
will lead to the creation of bioengineered microenvironments that can restrict metastatic disease 
progression. Mimicking the embryonic microenvironment to reprogram metastatic cancer cells to less 
invasive phenotype has great potential to transform the ways in which cancer is treated in the future. Int. J. Mol. Sci. 2011, 12                      
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Figure 3. Inhibitory effects of bioengineered ES cell microenvironments on metastatic 
cancer  cells.  (a) Cell proliferation;  (b)  Cell migration. Mouse  ES  cells in 3D alginate 
hydrogel beads (3D-ESC) significantly inhibited the proliferation and migration of 
metastatic breast cancer cells while NIH 3T3 fibroblasts in 3D alginate hydrogel beads 
(3D-3T3) did not display the significant inhibitory effect. *** p < 0.001. **** p < 0.0001. 
 
5. Outlook 
Metastatic cancer cells interact dynamically with a microenvironment that facilitates plasticity, 
tumorigenicity and metastasis. The unique microenvironment of breast cancer cells plays an important 
role in the regulation of metastasis. The engineering of cancer cell microenvironments in vitro may allow 
improved study of breast cancer metastasis leading to the discovery of a mechanism that will reverse 
malignant tumor growth. Metastatic cancer cells and CSCs share aspects of their transcriptional program 
with ES cells and employ embryonic signaling pathways to drive EMT process. The presence of an ES 
cell-like gene signature is correlated to poor clinical outcome because the critical molecular messengers 
are  aberrantly expressed in tumor cells and  inhibitors are missing in tumor microenvironments. 
Microenvironments of undifferentiated ES cells have the potential to restrict tumor cell growth and 
metastasis,  as they might supply  molecular  messengers or inhibitors to regulate or reprogram the 
abnormal embryonic signaling pathway and restore normalcy.  Recent findings from our lab have 
demonstrated the capacity of a bioengineered embryonic microenvironment to inhibit breast cancer 
metastasis, proving its potential in identifying anti-tumor/anti-metastasis factors as well as restricting 
metastatic disease. In the future, human embryonic stem cells and metastatic breast cancer cells or 
cancer stem cells will be employed in this system as it is more clinically relevant. In addition, it is 
essential to explore the feasibility of using induced pluripotent stem (iPS) cells to create an in vitro 
embryonic microenvironment. We anticipate that a more in-depth  understanding of ES cell-breast 
cancer cell interactions will lead to the prevention and treatment of breast cancer metastasis.  
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